Business Wire

FSC-2023

15.3.2023 16:48:34 CET | Business Wire | Press release

Share
Leaders of the Global Financial Community Outline Positive Outlook for Sector as Financial Sector Conference Opens in Riyadh

The second edition of the Financial Sector Conference (FSC 2023) opened today in Riyadh, welcoming over 3000 participants from around the world to discuss the way ahead for the global financial community under the conference theme of “Promising Financial Prospects.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005659/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Saudi Minister of Finance HE Mohammed Al-Jadaan addresses delegates at opening of Financial Sector Conference in Riyadh, Saudi Arabia (Photo: AETOSWire)

Welcoming delegates to the conference Saudi Minister of Finance HE Mohammed Al-Jadaan said: “I am confident that this conference will be an opportunity to build on experiences and share ideas to address a global economy which is full of challenges and opportunities—helping to make the global financial sector stronger, more influential and resilient.”

The conference opened with a powerful panel discussion examining the strategic options for the financial sector in light of challenging global economic circumstances. Credit Suisse Group AG Chairman Axel Lehmann told the audience: “What is clear is that over the past 10 to 15 years the massive geopolitical shifts we have seen are generating new economic opportunities in places like the Middle East which is becoming a vibrant new global centre along with places such as China and India.”

Commenting on opportunities emerging in Saudi Arabia, State Street Chairman and CEO Ronald O’Hanley added: “For investors it is clearly a very attractive time to be here with a strong economy and a Government that is committed to transition and powered by a well-educated workforce. There are clear investment opportunities in energy and renewables, in tourism and to benefit from the rise in the consumer economy.”

HE Eng. Khalid Al Falih, Saudi Arabia’s Minister of Investment, said: “We are now halfway to implementing Vision 2030 that will triple the scale of the economy and we are ahead of schedule but we know we cannot be complacent. One of the biggest shifts emerging is that in the past we were seen as a source of capital but that is being reversed today and we are urging the financial community to be aware of the opportunities and we aim to attract more capital and international partners.”

Alexandre Fleury, Co-Head of Market Activities, Societe Generale, told the conference: “Vision 2030 is extraordinary and an amazing achievement. But the world has not noticed enough what is happening in Saudi Arabia but soon investors will have no choice but to invest here. Global investors have to be a part of Vision 2030.”

Looking at the global economic situation, Seth Carpenter, Global Chief Economist, Morgan Stanley, “As Morgan Stanley, we are pretty optimistic about Asia, specifically China, Japan, India and Saudi Arabia. The weakest growth is in Europe and the US although economic performance is high. The quandary for central banks is how much you raise interest rates in order to bring inflation down; and judging exactly how much you need to slow things down without causing a recession.”

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005659/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye